Related Experiment Video

Updated: Jul 13, 2026

Analysis of Nonhomologous End Joining and Homologous Recombination Efficiency in HEK-293T Cells Using GFP-Based Reporter Systems
09:29

Analysis of Nonhomologous End Joining and Homologous Recombination Efficiency in HEK-293T Cells Using GFP-Based Reporter Systems

Published on: February 2, 2024

Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone

Melissa S Bentle1, Kathryn E Reinicke, Ying Dong

  • 1Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.

Cancer Research
|July 20, 2007
PubMed

Insights

Beta-lapachone (beta-lap) triggers DNA repair pathways in cancer cells. Inhibiting nonhomologous end joining (NHEJ) enhances beta-lap

Area of Science:

  • Molecular Biology
  • Cancer Research
  • DNA Repair Mechanisms

Background:

  • DNA double-strand breaks (DSBs) are induced by antitumor agents, activating homologous recombination (HR) and nonhomologous end joining (NHEJ) repair pathways.
  • These pathways involve kinases like ATM, ATR, and DNA-PKcs, and their dysregulation can lead to drug resistance and genomic instability.
  • Beta-lapachone (beta-lap), a novel agent in pancreatic cancer trials, induces cell death in NQO1-overexpressing cancer cells via ROS generation and DNA damage.

Purpose of the Study:

  • To investigate the DNA repair pathways activated by beta-lapachone (beta-lap) in NQO1-expressing cancer cells.
  • To determine the role of HR and NHEJ in beta-lap-induced cell death and radiosensitization.
  • To identify potential therapeutic targets for enhancing beta-lap efficacy.

Main Methods:

  • Treatment of cancer cells with beta-lapachone.
  • Assessment of DNA damage response pathways, including MRE11-Rad50-Nbs-1 complex activation and phosphorylation of ATM, DNA-PKcs, and Chk1.
  • Inhibition of HR and NHEJ pathways using genetic or chemical methods to evaluate their impact on beta-lap lethality.

Main Results:

  • Beta-lap exposure activated the MRE11-Rad50-Nbs-1 complex in an NQO1-dependent manner.
  • Simultaneous activation of both HR and NHEJ pathways was indicated by the phosphorylation of ATM, DNA-PKcs, and Chk1.
  • Inhibition of NHEJ, but not HR, significantly potentiated beta-lap-induced cancer cell death.

Conclusions:

  • Beta-lapachone activates both HR and NHEJ DNA repair pathways in NQO1-expressing cancer cells.
  • NHEJ is identified as a critical pathway that, when inhibited, enhances the cytotoxic effects of beta-lap.
  • Targeting NHEJ presents a promising strategy to improve the therapeutic efficacy of beta-lap, alone or in combination therapies.

Related Concept Videos

Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Fixing Double-strand Breaks02:04

Fixing Double-strand Breaks

The double-stranded structure of DNA has two major advantages. First, it serves as a safe repository of genetic information where one strand serves as the back-up in case the other strand is damaged. Second, the double-helical structure can be wrapped around proteins called histones to form nucleosomes, which can then be tightly wound to form chromosomes. This way, DNA chains up to 2 inches long can be contained within microscopic structures in a cell. A double-stranded break not only damages...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...